Establishment and application of high throughput screening model for influenza virus neuraminidase inhibitors in vitro

Yaoxue Xuebao

Volumn 37, Issue 12, 2002, Pages 930-933

  Cao, Hong Peng ^a   Tao, Pei Zhen ^a   Du, Guan Hua ^b  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Influenza A and B; Neuraminidase; Screening model

Indexed keywords

EID: 0042236563     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Calfee DP, Hayden FG. New approaches to influenza chemotherapy neuraminidase inhibitors [J] . Drugs, 1998,56 (4):537-553.
2. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors [J]. Lancet 2000,355(9206):827 -835.
3. Khare MD, Sharland M. Influenza [J]. Exp Opin Pharmacother, 2000,1(3):367-375.
4. Cox NJ, Subbarao K. Influenza [J]. Lancet, 1999, 354 (9186):1277-1282.
5. Kandel R, Hartshorn KL. Prophylaxis and treatment of influenza virus infection [J]. BioDrug 2001, 15 (5):303-323.
6. Cheer SM, Wagstaff AJ. Zanamivir: an update of its use in influenza [J] . Drugs , 2002,62(1):71-106.
7. Tai CY, Escarpe PA, Sidwell RW, et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS4071 [J]. Antimicrob Agents Chemother, 1998,42(12):3234-3241.
8. Potier M, Mameli L, Belisle M, et al. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D-N-acetylneuraminate) substrate [J]. Anal Biochem, 1979,94: 287-296.